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OBJECTIVES The objective of the study was to determine whether the occurrence of shocks for ventricular
tachyarrhythmias during therapy with implantable cardioverter-defibrillators (ICD) is pre-
dictive of shortened survival.
BACKGROUND Ventricular tachyarrhythmias eliciting shocks are often associated with depressed ventricular
function, making assessment of shocks as an independent risk factor difficult.
METHODS Consecutive patients (n 5 421) with a mean follow-up of 756 6 523 days were classified into
those who had received no shock (n 5 262) or either one of two shock types, defined as single
(n 5 111) or multiple shocks (n 5 48) per arrhythmia episode. Endpoints were all-cause and
cardiac deaths. A survival analysis using a stepwise proportional hazards model evaluated the
influence of two primary variables, shock type and left ventricular ejection fraction (LVEF
,35% or .35%). Covariates analyzed were age, gender, NYHA Class, coronary artery
disease, myocardial infarction, coronary revascularization, defibrillation threshold and tachy-
arrhythmia inducibility.
RESULTS The most complete model retained LVEF (p 5 0.005) and age (p 5 0.023) for the
comparison of any shock versus no shock (p 5 0.031). The occurrence of any versus no shock,
or of multiple versus single shocks significantly decreased survival at four years, and these
differences persisted after adjustment for LVEF. In the LVEF subgroups ,35% and ,25%,
occurrence of multiple versus no shock more than doubled the risk of death. Compared with
the most favorable group LVEF $35% and no shock, risk in the group multiple shocks and
LVEF ,35% was increased 16-fold.
CONCLUSIONS In defibrillator recipients, shocks act as potent predictors of survival independent of several
other risk factors, particularly ejection fraction. (J Am Coll Cardiol 1999;34:204–10) © 1999
by the American College of Cardiology
Identification of high-risk patients undergoing implantable
cardioverter-defibrillator (ICD) therapy is essential for the
planning and implementation of appropriate therapy. One
important question is whether ventricular tachycardia (VT)
and ventricular fibrillation (VF) detected and treated by
implanted defibrillators provide useful prognostic informa-
tion. In some reports, the occurrence of shocks acted as a
marker of poor outcome (1–3), but in several others it did
not (4–8). In one study, ICD therapy was a risk factor only
when more than one shock was delivered per arrhythmia
episode (9). One difficulty in interpreting previous reports is
that the occurrence of shocks was associated with a de-
pressed left ventricular ejection fraction (LVEF) (2,9), an
important predictor of survival (8,10,11). Therefore, shock
therapies as an independent predictor of survival remained
uncertain.
In the present study we performed a survival analysis in
421 consecutive patients receiving ICD treatment to deter-
mine whether the detection and treatment of ventricular
tachyarrhythmias verified by an electrogram (EGM) are
useful for the prediction of clinical outcome. The analysis
included a stratification by LVEF and considered multiple
variables of potential influence.
METHODS
Patients. Consecutive patients (n 5 421) of either sex
receiving first-time ICD implantation were included in the
study. Indication for ICD therapy was at least one episode
of aborted sudden cardiac death (SCD) or recurrent epi-
sodes of symptomatic VT. Contraindications for ICD
therapy were ventricular arrhythmias associated with acute
coronary syndromes, reversible causes of ventricular tachy-
arrhythmias, and diseases predicted to limit life expectancy
to less than six months. All patients received an estimation
of LVEF by radionuclide ventriculography, contrast angiog-
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raphy or echocardiography, a coronary arteriography, and a
preoperative electrophysiologic study (EPS).
Implantation of cardioverter-defibrillators and elec-
trodes. Defibrillators implanted were new-generation
tiered-therapy devices with EGM capability. All ICDs used
were capable of delivering four or more therapies per
episode of detected tachyarrhythmia. High-voltage elec-
trodes consisted of a right ventricular electrode in combi-
nation with a superior vena electrode or a generator shell
electrode (active can design). Other configurations included
dual Endotak coil electrodes or a third high-voltage elec-
trode.
Defibrillation threshold testing. For the determination of
defibrillation thresholds (DFTs), a step-down scheme was
used as previously reported (12,13). The requirement of a
minimal 10-J margin of safety between the DFT and the
maximum output of the generators was met in all cases. All
devices were programmed to deliver biphasic defibrillation
shocks at the maximum output of the generators (range of
nominal outputs 29 J to 37.4 J).
Follow-up. Follow-up included visits at one and three
months, and then at three-month intervals until the end of
the study or death. The DFT was redetermined at the
three-month visit. Additional visits were scheduled when-
ever patients experienced shocks or ICD-related complica-
tions.
Definitions. Appropriate shock: Shocks were called appro-
priate when stored EGMs met the programmed criteria of
VT or VF detection. The EGM criteria for the diagnosis of
VT included changes in the number and polarity of the
QRS deflections during the tachycardia compared with that
during the baseline rhythm (14). The EGMs were inter-
preted taking surface electrocardiographic information and
clinical context into consideration (15). Inappropriate shock:
Shocks were associated with EGM failing to exhibit interval
and morphologic criteria of VT or VF. Single shock (SS)
subgroup: patients who received appropriate successful single
shocks, but never multiple shocks. Multiple shock (MS)
subgroup: patients who received a rapid sequence of two or
more appropriate shocks during a single episode of ventric-
ular tachyarrhythmia. These patients may or may not have
received single shocks at other times. Multiple shocks as
defined here should be distinguished from shocks in clusters
(storms, salvos), terms often used to denote frequent shocks
elicited over short periods (minutes to hours) in response to
temporally discrete, independently detected arrhythmic
events. Single or multiple shocks delivered on the day of
death were considered to be part of terminal arrhythmias
and were not included in the analysis. No shock (NS)
subgroup: patients who received neither SS nor MS. Any
shock (SS, MS) group: sum of the nonoverlapping SS and MS
subgroups. Sudden cardiac death (SCD): the time-based
definition of death within 1 h of onset of symptoms was
used. Ventricular tachycardia: ventricular tachycardia was
defined as $3 consecutive ventricular beats at a rate $110
beats/min.
Data collection. Selected demographic, historic and labo-
ratory data totaling 112 variables were entered into a
continually updated dBase database (versions IV or V,
Borland). Although study end points were defined retro-
spectively, the data used, including those derived from
electrograms, were entered prospectively into the data bank.
Before data analysis, the data bank was independently
edited by two investigators (L.L.F. and F.C-S.). Patient
records were consulted in case of deficiencies or suspected
entry errors detected during database review.
Statistical analysis. To determine the comparability of
groups assembled according to shock therapies, data were
subjected to one-way analysis of variance (continuous vari-
ables) or Pearson’s chi-square test (categorical variables).
Specific comparisons included those between patients re-
ceiving no shocks (NS) versus any shocks (SS, MS) or single
shocks only (SS) versus multiple-shocks (MS).
Stepwise proportional hazard regression (16) was per-
formed to model and determine the relationship between
patient survival times and different shock therapies, control-
ling for selected prognostic factors, in particular categorical
LVEF (,, $35%; ,, $25%). Assessment was made of age,
sex, body mass index (BMI), New York Heart Association
(NYHA) class, coronary artery disease (CAD), acute myo-
cardial infarction (AMI), coronary artery bypass graft
(CABG), nonischemic cardiomyopathy, cardiac resuscita-
tion (aborted sudden cardiac death), VT inducibility, DFT,
antitachycardia pacing (ATP) and amiodarone or sotalol
therapy as potential covariates in the model. A backward
elimination procedure was used for the selection of candi-
date variables shown to be significant at p , 0.25 by the
Wald test. The final model included variables that were
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ATP 5 antitachycardia pacing
BMI 5 body mass index
CABG 5 coronary artery bypass graft
CAD 5 coronary artery disease
DFT 5 defibrillation threshold
EGM 5 electrogram
EPS 5 electrophysiologic study
ICD 5 implantable cardioverter-defibrillator
LVEF 5 left ventricular ejection fraction
MS 5 subgroup receiving multiple and possibly also
single shocks
NS 5 subgroup receiving no shock
NYHA 5 New York Heart Association
SCD 5 sudden cardiac death
SS 5 subgroup receiving single but not multiple
shocks
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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statistically significant, at least at the 5% level. End points of
interest were all-cause mortality and cardiac mortality.
Survival probabilities were assessed using the Kaplan-
Meier product limit method. Adjusted estimates of survivor
functions were based on alive and dead counts reweighted
according to the relative hazards estimated by the Cox
proportional hazards covariate model. These adjustments
should not be viewed to have the same meaning as those in
an ordinary regression problem. Survivor functions for the
shock subgroups were stratified by LVEF (,, $35%; ,,
$25%) and compared for equality by the stratified log-rank
test. All statistical calculations were performed using
STATA statistical software (Stata Corporation, College
Station, Texas).
RESULTS
Patient characteristics. Clinical characteristics for the en-
tire cohort and for the shock treatment subgroups are shown
in Table 1. Characteristics in the subgroups were generally
similar and resembled those of 18 ICD studies recently
analyzed (12). There were no significant intergroup differ-
ences for male prevalence, BMI, angiographically verified
CAD, and histories of AMI, CABG and aborted SCD.
The mean LVEF was 34 6 12% in the entire cohort, 36 6
12% in the no shock subgroup (NS), and 31 6 11% both in
the single (SS) and multiple shock (MS) subgroups. The
LVEF values for MS or SS compared with NS were
significantly depressed (p , 0.001) (Table 1). Compared
with NS, there were a significantly (p , 0.001) greater
proportion of patients with any shock (SS, MS) under the
stratifications of LVEF ,35% (107/159 5 67%) and LVEF
,25% (69/159 5 43%) (Table 1).
Electrophysiologic study. At preimplantation EPS, pro-
grammed stimulation in 421 patients induced monomor-
phic VT in 77% (325), VF in 3% (13), polymorphic VT in
0.7% (3), and no inducible arrhythmia in 19% (80) of the
patients. Corresponding percents were 78% (204), 3% (9),
0.7% (2), and 18% (47) for the NS subgroup (n 5 262); 78%
(87), 4% (4), 0.8% (1), and 17% (19) for the SS subgroup
(n 5 111); and 91% (44), 3% (1), 0% (0), and 6% (3) for the
MS subgroup (n 5 48).
Device programming. Programmed interval limits for the
detection and treatment of VT in the NS, SS, and MS
subgroups averaged 344 6 32, 349 6 35, 356 6 34 ms, and
corresponding limits for VF were 296 6 13, 298 6 14, and
299 6 19 ms. Intergroup differences were not significant.
The ATP was “on” at some time during follow up in 48% of
the patients (201/421), and 44% of these (88/201) received
at least one appropriate ATP therapy. In the NS, SS and
MS subgroups, the percentages of patients with ATP
programmed “on” were 45% (118/262), 51% (57/111), and
54% (26/48). In the corresponding groups, the percents for
ATP used at least once were 42% (49/118), 44% (25/57)
and 54% (14/26). The ATP treatment was successful in the
NS, SS and MS subgroups in 96%, 92%, and 86% of the
episodes. Acceleration of the tachycardia in response to
ATP was below 2% in all groups. None of the intergroup
differences between parameters of ATP therapy were sig-
nificant.
Antiarrhythmic drug therapy. At discharge, the percent-
ages of patients receiving amiodarone in the NS, SS and MS
subgroups were 5% (13/262), 14% (16/111), and 29%
(14/48) (p , 0.05 for NS vs. MS). The percentage of
patients receiving amiodarone was 9% (34/366) in survivors
compared with 16% (9/55) in nonsurvivors (p . 0.05). The
percentage of patients discharged on beta-adrenergic block-
ing agents did not differ between groups, averaging 22%
(58/266) for NS, 19% (21/111) for SS, and 21% (10/48) for








Number of cases 421 262 111 48 —
Age (yrs) 63 6 11 64 6 11 61 6 12 61 6 10 0.029/0.844
Male (%) 84 82 86 90 0.237/0.494
BMI (kg/m2) 27 6 4 27 6 4 27 6 4 27 6 4 0.766/0.853
CAD (%) 82 84 75 90 0.261/0.035
SCD (%) 46 47 45 42 0.560/0.694
AMI (%) 54 56 49 52 0.175/0.691
CABG (%) 47 47 51 44 0.683/0.798
Class I/II/II (%)‡ 32/62/6 39/55/6 21/72/7 19/79/2 ,0.001/0.397
LVEF (%) 34 6 12 36 6 12 31 6 11 31 6 11 ,0.001/0.954
,35% (%) 52 42 66 71 ,0.001/0.532
,25% (%) 32 26 46 38 ,0.001/0.324
Follow up (days)§ 756 6 523 637 6 489 925 6 483 1015 6 594 —
Total deaths 55 (13%) 16 (6%) 19 (17%) 20 (42%) —
Cardiac deaths 44 (10%) 12 (5%) 16 (14%) 16 (33%) —
Continuous data are presented as mean 6 SD.
*p-Value for comparison NS vs. (SS1MS). †p-Value for SS vs. MS. ‡New York Heart Association functional class. §Follow-up days from implant to death or end of study.
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MS. Compared with values at discharge, values at 12 and 24
months did nor differ significantly.
Shock therapies. Among the 421 patients, 195 (46%)
experienced shocks. These were appropriate in 159 patients
and inappropriate in 36, with 4 patients assessed to have
received both appropriate and inappropriate shocks. Major
causes of inappropriate shocks included atrial fibrillation/
flutter in 16 cases and lead complications in 12 cases. All but
one patient receiving MS (n 5 48) experienced additional
SS. Among the 47 patients receiving both shock types, SS
preceded MS in 15 patients, SS followed MS in 15 patients,
and SS occurred on the same day as MS in 17 patients.
Repeated shocks received as part of a terminal syndrome
were by definition excluded.
Survival analysis. The numbers of total (all-cause) deaths
and total cardiac deaths (nonsudden/sudden) were 16 and
12 (8/4) for NS, 19 and 16 (13/3) for SS, and 20 and 16
(13/3) for MS. The mean intervals from implant to the end
of the study or death in the entire cohort and in shock
subgroups are shown in Table 1. The intervals from im-
plantation to first appropriate shock averaged 398 6 395
days for any shock (SS, MS), 416 6 402 days for SS and
408 6 402 days for MS. For deaths due to all-cause, the
average intervals from first SS to death and first MS to
death were essentially the same, averaging 354 6 288 (n 5
19) and 348 6 280 (n 5 20) days. In patients receiving both
SS and MS, the subgroups with SS occurring before (6
deaths), after (9 deaths), or on the same day as MS (5
deaths) had similar survival (respective Kaplan-Meier esti-
mates at three years 0.81, 0.73 and 0.85).
The occurrence of any shock versus NS, or MS versus SS
decreased survival at four years, and this difference persisted
after adjustment for categorical LVEF (Table 2 and Fig. 1).
A stratified log rank test (Table 3) indicated a significant
difference in the survival functions between any shock versus
NS (p 5 0.0520) and between MS versus SS (p 5 0.0058).
Within each stratum, the difference is mostly attributed to
LVEF $35% for the comparison of any shock versus NS
(p 5 0.0034, Fig. 2) and to LVEF ,35 for the comparison
of MS versus SS (p 5 0.0055, Fig. 3). Similar intergroup
relations were obtained when LVEF was stratified at the
25% level (survival curves not shown).
The results of initially fitting the full model on all
prognostic variables considering all-cause mortality with the
retention of any shock (compared with NS) and LVEF
,35% (compared to LVEF $35%) in the model demon-
strated three variables to be significant: any shock (p 5
Figure 1. Kaplan-Meier survival curves for patient groups receiv-
ing different types of ICD shock therapies. Top panel: unadjusted
for LVEF. Lower panels: adjusted for categorical LVEF. In this
and in subsequent figures, NS, SS, MS and (SS, MS) indicate no
shock, single shock, multiple shocks and any shock as defined in
Methods section.
Table 2. All-cause Mortality for Groups Receiving Different
Shock Therapies After Adjustment for Categorical LVEF
Shock Therapy
Proportion Surviving
1 Year 2 Years 4 Years
No Shock (NS) 0.99 (0.98) 0.97 (0.95) 0.89 (0.82)
Any Shock (SS, MS) 0.98 (0.95) 0.94 (0.86) 0.83 (0.64)
Single Shock (SS) 0.98 (0.97) 0.93 (0.91) 0.80 (0.71)
Multiple Shocks (MS) 0.94 (0.92) 0.85 (0.78) 0.67 (0.55)
Numbers in parentheses denote corresponding unadjusted proportions.
Table 3. All-Cause Mortality for Groups Receiving Different




No Shock (NS) 0.0520 0.4649 0.0034
vs.
Any Shock (SS, MS)
Single Shock (SS) 0.0058 0.0055 0.5452
vs.
Multiple Shocks (MS)
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0.031), LVEF ,35% (p 5 0.005) and age (p 5 0.023)
(Table 4). The interaction term of any shock by LVEF
,35% was evaluated and shown to add only a slight
improvement to the model (G 5 3.68, p , 0.10). There was
a slight increase in the risk of dying the older the patient
was, with an estimated hazard ratio of 1.4 (per 10-year
increase). Very similar modeling results were seen when
considering cardiac mortality, though without significant
contribution of age.
When fitting the full model with MS (compared to SS)
and with LVEF ,35% retained in the model, MS (p 5
0.013) but not LVEF ,35% (p 5 0.136) was significant for
all-cause mortality (Table 4). No significant interaction was
detected. The risk of cardiac mortality was increased about
twofold for patients with the occurrence of any shock (vs.
NS, p 5 0.051) or with the occurrence of MS (vs. SS, p 5
0.035).
Hazard ratios stratified on both categorical LVEF and
shock subgroup are listed in Table 5. Compared with the
most favorable prognostic group with LVEF $35% and
NS, depression in LVEF below 35% increased the risk of
dying about 7-fold, and when LVEF ,35% was combined
with MS, the risk was increased 16-fold. Compared with
the reference group LVEF $25% and NS, the hazard ratios
were 11.2 for the group LVEF ,25% with NS, and 23.4 for
the group LVEF ,25% with MS. Thus, both at the ,35%
and ,25% LVEF depression levels, occurrence of multiple
shocks versus no shock more that doubled the risk of dying.
DISCUSSION
Our study is in agreement with previous reports indicating
the importance of LVEF as a prognostic indicator of sur-
vival in patients receiving ICD therapy (1–3). Conversely,
our results do not support the conclusion that appropriate
ICD shocks for ventricular tachyarrhythmias have no or
little prognostic implications (4–8). Both the occurrence of
any shock versus no shock and multiple shocks for single
arrhythmia episodes versus single shocks were associated
with significantly lower survival probabilities.
This report is the first to examine in detail the interac-
tions between LVEF and shock therapy on survival. The
results demonstrate that an increased risk of dying persisted
after adjustment for LVEF and that both shock and shock
types acted as potent independent risk factors. Compared
with the prognostically most favorable group (no shock and
LVEF $35%), the occurrence of single shocks increased the
risk of death more than 5-fold irrespective of whether
LVEF was more or less than 35%. Also, the combination of
an LVEF of less than 35% and a history of multiple shocks
for single arrhythmia episodes identified a group with a
16-fold increased risk of dying. Controlled trials indicate
that ICDs are effective in preventing sudden cardiac death
(17,18), and in large series refractoriness to ICD therapy
occurred in less than 2% of the patients (19). Here, we
demonstrate that it is possible to identify special subsets of
patients at high risk despite ICD therapy.
In the report by Villacastin et al. (9), 80 patients were
grouped without the availability of EGMs into those
Figure 2. Kaplan-Meier survival probability stratified according to
LVEF: comparison of any versus no shock. Upper panel: LVEF
,35%. Lower panel: LVEF $35%. Abbreviations as in Figure 1
legend.
Figure 3. Kaplan-Meier survival probability stratified according to
LVEF: comparison of multiple versus single shocks. Upper panel:
LVEF ,35%. Lower panel: LVEF $35%. Abbreviations as in
Figure 1 legend.
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receiving no shock (n 5 38), single shocks (n 5 26), and
multiple consecutive shocks for single arrhythmia episodes
(n 5 16). In agreement with our findings, results of their
proportional hazards regression analysis suggested that the
occurrence of multiple shocks was a marker of poor prog-
nosis (9). In contrast, they (9) concluded that single shocks
did not influence survival compared with no shock, a result
that appeared to confer prognostic significance exclusively to
multiple consecutive shocks. However, the numbers of
deaths in the no-shock (3 deaths), single-shock (2 deaths),
and multiple consecutive shock groups (7 deaths) appeared
small to perform valid survival analyses. A confounding
feature of the study by Villacastin et al. (9) was that the
mean ejection fraction in the multiple consecutive shock
group was substantially depressed compared with that in
either the single or no-shock groups (26 6 4% vs. 39 6 3%
or 43 6 2%).
In the study by Zilo et al. (2), 32 patients receiving shocks
compared with 21 receiving no shocks had a lower three-
year survival rate, but patients with a history of shocks again
exhibited lower ejection fractions compared with shock-free
patients (27 6 14% vs. 36 6 15%). In these studies (2,9), it
remains unclear whether shock therapy was a risk factor
independent of depressed ventricular function, an estab-
lished risk factor in patients receiving ICD therapy (8,10).
In our analysis, the only variable associated with a change
in survival besides LVEF and shock therapies was the age of
the patients. Our results indicate that the arrhythmic history
before implantation (presenting arrhythmia) did not act as
an important prognostic factor, in apparent agreement with
the ESVEM trial (11). Our results are also in agreement
with those of the AVID trial (17,20), suggesting that
inducibility of VT at baseline EPS is not prognostic of
increased total mortality. The value of VT inducibility as a
prognostic factor of sudden death independent of left
ventricular function remains a controversial issue (21,22).
Study limitations. This mortality study was not designed
as a prospective trial. However, data used were based on a
continually updated data bank. Because the study included
consecutive patients, we believe that data collection was not
biased or restricted to subsets fitting special prerequisites.
Conclusions. In consecutive ICD recipients not selected
according to special inclusion/exclusion criteria, single or
repetitive shocks for single episodes of ventricular tachyar-
rhythmias were risk factors for total and cardiac mortality
independent of ventricular function. In addition, combined
occurrence of multiple shocks and a low ejection fraction
identified a subgroup with a poor prognosis.
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